Patent Pending: Methods and Compositions for Treatment of Immune-Mediated Disorders

A novel nanoparticle platform has been developed that induces and expands multiple populations of suppressive regulatory cells In Vivo for the prevention and termination of immune-mediated disorders.  These include autoimmune diseases, graft-versus-host disease, and transplant rejection.  The regulatory cells expanded include both CD4+ and CD8+ T cells and NK cells.   The nanoparticles function as artificial acellular antigen-presenting cells (aAPC) that target T cells and NK cells and provide them the essential stimulation and cytokines they require for regulatory cell generation, function, and expansion.  This is achieved without the use of the toxic immunosuppressive and biological agents now in use.